IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

)	
In re:)	Chapter 11
)	
AKORN, INC., et al., ¹)	Case No. 20-11177 (KBO)
)	
	Debtors.)	(Jointly Administered)
)	

NOTICE OF FILING OF PLAN SUPPLEMENT

PLEASE TAKE NOTICE THAT on July 2, 2020, United States Bankruptcy Court for "Court") of Delaware (the entered an order [Docket No. 318] (the "Disclosure Statement Order"): (a) authorizing Akorn, Inc. and its affiliated debtors and debtors in possession (collectively, the "Debtors"), to solicit acceptances for the Joint Chapter 11 Plan of Akorn, Inc. and Its Debtor Affiliates (as may be modified, amended, or supplemented from time to time, the "Plan");2 (b) approving the Disclosure Statement for Joint Chapter 11 Plan of Akorn, Inc. and Its Debtor Affiliates (the "Disclosure Statement") as containing "adequate information" pursuant to section 1125 of the Bankruptcy Code; (c) approving the solicitation materials and documents to be included in the Solicitation Packages; and (d) approving procedures for soliciting, receiving, and tabulating votes on the Plan and for filing objections to the Plan.

PLEASE TAKE FURTHER NOTICE THAT as contemplated by the Plan and the Disclosure Statement Order approving the Disclosure Statement, the Debtors hereby file the following Plan Supplement exhibits (each as defined in the Plan): (a) the Assumed Contracts and Leases List; (b) the identity of the Plan Administrator and the terms of compensation of the Plan Administrator; (c) Schedule of Retained Causes of Action; and (d) the Description of Transactions Steps, each of which shall be consistent with the Restructuring Support Agreement and acceptable in form and substance to the Debtors and the Required Consenting Term Loan Lenders, *provided that*, through the Effective Date, the Plan Supplement and the exhibits thereto as may be modified, amended, or supplemented from time to time in accordance with this Plan and the Restructuring Support Agreement, *provided further* that any such amendment or modification shall be reasonably acceptable in form and substance to the Debtors and the Required Consenting Term Loan Lenders.

Capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Plan.



The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number, if any, are: Akorn, Inc. (7400); 10 Edison Street LLC (7890); 13 Edison Street LLC; Advanced Vision Research, Inc. (9046); Akorn (New Jersey), Inc. (1474); Akorn Animal Health, Inc. (6645); Akorn Ophthalmics, Inc. (6266); Akorn Sales, Inc. (7866); Clover Pharmaceuticals Corp. (3735); Covenant Pharma, Inc. (0115); Hi-Tech Pharmacal Co., Inc. (8720); Inspire Pharmaceuticals, Inc. (9022); Oak Pharmaceuticals, Inc. (6647); Olta Pharmaceuticals Corp. (3621); VersaPharm Incorporated (6739); VPI Holdings Corp. (6716); and VPI Holdings Sub, LLC. The location of the Debtors' service address is: 1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045.

PLEASE TAKE FURTHER NOTICE THAT the hearing at which the Court will consider confirmation of the Plan (the "<u>Confirmation Hearing</u>") will commence <u>on August 20, 2020, at 1:00 p.m., prevailing Eastern Time</u> before the Honorable Karen B. Owens, in the United States Bankruptcy Court for the District of Delaware, located at 824 N. Market Street, Sixth Floor, Wilmington, Delaware 19801.

PLEASE TAKE FURTHER NOTICE THAT the deadline for filing objections to the Plan is <u>August 14, 2020, at 4:00 p.m.</u>, prevailing Eastern Time (the "<u>Confirmation Objection Deadline</u>"). Any objection to the Plan *must*: (a) be in writing, (b) conform to the Bankruptcy Rules, the Local Rules, and any orders of the Court, (c) state, with particularity, the basis and nature of any objection to the Plan and, if practicable, a proposed modification to the Plan that would resolve such objection, and (d) be filed with the Court (contemporaneously with a proof of service).

PLEASE TAKE FURTHER NOTICE THAT if you would like to obtain a copy of the Disclosure Statement, the Plan, the Plan Supplement, or related documents, you should contact Kurtzman Carson Consultants LLC, the notice and claims agent retained by the Debtors in the chapter 11 cases (the "Notice and Claims Agent"), by: (a) calling the Notice and Claims Agent at (877) 725-7539, (U.S. and Canada) or (424) 236-7247, (International); (b) visiting the Debtors' restructuring website at: https://www.kccllc.net/akorn; (c) writing to the Notice and Claims Agent at Akorn Ballot Processing Center, c/o KCC, 222 N. Pacific Coast Highway, Suite 300, El Segundo, California 90245; and/or (d) emailing AkornInfo@kccllc.com and requesting paper copies of the corresponding materials previously received in electronic format (to be provided at the Debtors' expense). You may also obtain copies of any pleadings filed in the chapter 11 cases for a fee via PACER at: https://ecf.deb.uscourts.gov.

ARTICLE VIII OF THE PLAN CONTAINS RELEASE, EXCULPATION, AND INJUNCTION PROVISIONS, AND ARTICLE VIII.F CONTAINS A THIRD-PARTY RELEASE. THUS, YOU ARE ADVISED TO REVIEW AND CONSIDER THE PLAN CAREFULLY BECAUSE YOUR RIGHTS MIGHT BE AFFECTED THEREUNDER.

THIS NOTICE IS BEING SENT TO YOU FOR INFORMATIONAL PURPOSES ONLY. IF YOU HAVE QUESTIONS WITH RESPECT TO YOUR RIGHTS UNDER THE PLAN OR ABOUT ANYTHING STATED HEREIN OR IF YOU WOULD LIKE TO OBTAIN ADDITIONAL INFORMATION, CONTACT THE NOTICE AND CLAIMS AGENT.

[Remainder of page intentionally left blank]

Wilmington, Delaware August 7, 2020

/s/ Paul N. Heath

RICHARDS, LAYTON & FINGER, P.A.

Paul N. Heath (No. 3704) Amanda R. Steele (No. 5530) Zachary I. Shapiro (No. 5103) Brett M. Haywood (No. 6166)

One Rodney Square 920 N. King Street

Wilmington, Delaware 19801
Telephone: (302) 651-7700
Facsimile: (302) 651-7701
Email: heath@rlf.com
steele@rlf.com
shapiro@rlf.com

Co-Counsel for the Debtors and Debtors in Possession

haywood@rlf.com

KIRKLAND & ELLIS LLP KIRKLAND & ELLIS INTERNATIONAL LLP

Patrick J. Nash, Jr., P.C. (admitted *pro hac vice*) Gregory F. Pesce (admitted *pro hac vice*) Christopher M. Hayes (admitted *pro hac vice*) 300 North LaSalle Street

Chicago, Illinois 60654 Telephone: (312) 862-2000 Facsimile: (312) 862-2200

> patrick.nash@kirkland.com gregory.pesce@kirkland.com christopher.hayes@kirkland.com

-and-

KIRKLAND & ELLIS LLP KIRKLAND & ELLIS INTERNATIONAL LLP

Nicole L. Greenblatt, P.C. (admitted pro hac vice)

601 Lexington Avenue

New York, New York 10022 Telephone: (212) 446-4800 Facsimile: (212) 446-4900

Email: nicole.greenblatt@kirkland.com

Co-Counsel for the

Debtors and Debtors in Possession

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

In re:)	Chapter 11
AKORN, INC., et al., ³)	Case No. 20-11177 (KBO)
	Debtors.)	(Jointly Administered)

PLAN SUPPLEMENT FOR JOINT CHAPTER 11 PLAN OF AKORN, INC. AND ITS DEBTOR AFFILIATES

Table of Contents

Exhibit A Schedule of Retained Causes of Action

Exhibit B Assumed Contracts and Leases List

Exhibit C Description of Transaction Steps

Exhibit D Identity and Terms of Compensation of the Plan Administrator

Certain documents, or portions thereof, contained in this Plan Supplement⁴ remain subject to continuing negotiations among the Debtors, the Required Consenting Term Loan Lenders, and other interested parties with respect thereto. The Debtors reserve all rights to amend, revise, or supplement the Plan Supplement, and any of the documents and designations contained herein, at any time before the Plan Effective Date, or any such other date in accordance with the Plan, the Confirmation Order, or any other order of the Bankruptcy Court. Each of the documents contained in the Plan Supplement or its amendments are subject to certain consent and approval rights to the extent provided in the Plan or Restructuring Support Agreement.

The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number, if any, are: Akorn, Inc. (7400); 10 Edison Street LLC (7890); 13 Edison Street LLC; Advanced Vision Research, Inc. (9046); Akorn (New Jersey), Inc. (1474); Akorn Animal Health, Inc. (6645); Akorn Ophthalmics, Inc. (6266); Akorn Sales, Inc. (7866); Clover Pharmaceuticals Corp. (3735); Covenant Pharma, Inc. (0115); Hi-Tech Pharmacal Co., Inc. (8720); Inspire Pharmaceuticals, Inc. (9022); Oak Pharmaceuticals, Inc. (6647); Olta Pharmaceuticals Corp. (3621); VersaPharm Incorporated (6739); VPI Holdings Corp. (6716); and VPI Holdings Sub, LLC. The location of the Debtors' service address is: 1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045.

⁴ Capitalized terms not otherwise defined herein shall have the same meanings as set forth in the *Joint Chapter 11 Plan of Akorn, Inc. and Its Debtor Affiliates* (as may be modified, amended, or supplemented from time to time, the "<u>Plan</u>").

Exhibit A

Schedule of Retained Causes of Action

Exhibit A

Schedule of Retained Causes of Action

This **Exhibit A** contains the Schedule of Retained Causes of Action. Certain documents, or portions thereof, contained in this **Exhibit A** and the Plan Supplement remain subject to continuing negotiations among the Debtors, the Required Consenting Term Loan Lenders, and other interested parties with respect thereto. All parties reserve all rights to amend, revise, or supplement the Plan Supplement, and any of the documents and designations contained herein, at any time before the Effective Date of the Plan, or any such other date as may be provided for in the Plan or by order of the Bankruptcy Court. Each of the documents contained in the Plan Supplement or its amendments are subject to certain consent and approval rights to the extent provided in the Plan, the Restructuring Support Agreement, the Sale Transaction Documentation, or the DIP Loan Documents.

Retained Causes of Action

Article IV.P of the Plan provides as follows:

Pursuant to the Sale Transaction Documentation, the Debtors assigned and transferred to the Purchaser all of the Transferred Causes of Action pursuant to the Sale Transaction Documentation in connection with the Sale Transaction. For the avoidance of doubt, the Debtors or the Plan Administrator, as applicable, will retain the right to enforce the terms of the Sale Transaction Documentation. Any Retained Causes of Action shall remain with the Debtors and shall vest with the Plan Administrator as of the Effective Date.

No Entity may rely on the absence of a specific reference in the Plan, the Plan Supplement, or the Disclosure Statement to any such Cause of Action against them as any indication that the Debtors will not pursue any and all available Causes of Actions against them. No preclusion doctrine, including the doctrines of *res judicata*, collateral estoppel, issue preclusion, claim preclusion (judicial, equitable, or otherwise), or laches, shall apply to such Causes of Action upon, after, or as a consequence of the Confirmation or Consummation.

No Entity may rely on the absence of a specific reference in the Plan, the Plan Supplement, the Disclosure Statement, DIP Loan Documents, or the Sale Transaction Documentation to any Cause of Action against them as any indication that the Debtors will not pursue any and all available Causes of Action against them.

The Debtors expressly reserve all rights to prosecute any and all Causes of Action against any Entity, except as otherwise expressly provided in the Plan, including Causes of Action that are not expressly identified in this **Exhibit A**.

Below are identified specific Causes of Actions expressly preserved by the Debtors, subject to the terms of the Plan and the information provided in this $\underline{\textbf{Exhibit A}}$.

Akorn, Inc.

Causes of Action Related to Litigation

Debtor	Counter Party Names	Counter Party / Notice Party Addresses	Debtor Position	Caption of Suit	Type of Claim or Nature of Proceeding	Case Number	Status	Nature
Akorn, Inc.	Provepharm, Inc.	ATTN: Felice B. Galant, Norton Rose Fulbright US LLP, 1301 Avenue of the Americas, New York, NY, 10019-6022	Defendant	Provepharm, Inc. v. Akorn, Inc.	False Advertising	Case No. 17-cv- 007087 (SJF) (AKT)	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc., Hi-Tech Pharmacal and Versapharm	Generic Pharmaceuticals Pricing Antitrust Litigation	ATTN: Dianne M. Nast, Esq., NastLaw LLC, 1101 Market Street, Suite 2801,	Defendant	In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724	Price Fixing Class Action	EPA MDL No. 16-MD- 2724	Active	Claims, defenses, crossclaims, and counter-claims related to

			l .			ı	ı	
		Philadelphia, PA, 19107						litigation and possible litigation.
		ATTN: Roberta						nugation.
		Liebenberg,						
		Esq., Fine,						
		Kaplan, and						
		Black R.P.C.,						
		One South Broad Street,						
		23rd Floor,						
		Philadelphia,						
		PA, 19107						
		ATTN: W.						
		Joseph Nielsen, Esq.,						
		Connecticut						
		Attorney						
		General's						
		Office, 55 Elm						
		St, Hartford, CT, 06106						
		ATTN: Jan P.						
		Levine, Esq., Pepper						
		Hamilton LLP,						
		3000 Two						
		Logan Square,						
		Eighteenth &						
		Arch Streets,						
		Philadelphia, PA, 19103-						
		2799						
Akorn, Inc.,	America's 1st	ATTN:	Defendant	America's 1st	Antitrust	190702094	Active	Claims,
Akorn Sales,	Choice of South	Anthony		Choice of South	Matter			defenses,
Inc., and Hi- Tech	Carolina, Inc.	Christina, Lowey		Carolina, Inc., et al.				crossclaims and
Pharmacal		Dannenberg		ui.				counter-claims
Co., Inc.		PC, One Tower						related to
		Bridge, 100						litigation and
		Front St., Suite						possible
		520, West Conshohocken,						litigation.
	DI C	PA, 19428-297	D. C. :	DI C :		2007000:=		GL :
Akorn, Inc., Akorn Sales,	Blue Cross and Blue Shield of	ATTN: Anthony	Defendant	Blue Cross and Blue Shield of	Antitrust matter	200500347	Active	Claims, defenses,
Inc., Hi-Tech	North Carolina,	Christina,		North Carolina,				crossclaims
Pharmacal	et al.	Lowey		et al.				and
Co., Inc., and		Dannenberg						counter-claims
Versapharm		PC, One Tower						related to
Inc.		Bridge, 100						litigation and
		Front St., Suite 520, West						possible litigation.
		Conshohocken,						nugation.
		PA, 19428-						
A1	Dana at 1	2977	N-4 1	D f '	Thind	C N	A -4:	Claima
Akorn, Inc.	Papa et al.	ATTN: Thomas H.	Not named (this is a	Roofer's Pension Fund v.	Third party subpoena for	Case No. 2:16-cv-	Active	Claims, defenses,
		Przybylowski,	third party	Papa, et al	Akorn	2805-MCA-		crossclaims
		Pomerantz	subpoena)	_	documents	LDW		and

Akorn, Inc., HHi-Tech Pharmacal Co., Inc.	State of Mississippi	LLP, 10 South LaSalle Street, Suite 3505, Chicago, IL, 60603 ATTN: George W Neville and Jacqueline H Ray, Office of the Mississippi Attorney General, P.O. Box 220, Jackson, MS,	Defendant	State of Mississippi v. ECR et. al.	Medicaid Reimbursment	25CH1:17- cv-000305 consolidated to 25CH1:17- cv-00304	Active	counter-claims related to litigation and possible litigation. Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc., 13 Edison Street LLC, Hi-Tech Pharmacal Co., Inc.	Jason Capozello	39205 ATTN: Robert Peragine, Cellino & Barnes, 532 Broadhollow Road, Suite 107, Melville, NY, 11747	Defendant	Capozello v. Akorn, et. al	Personal Injury	621087/17	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Reuben Bachrach	ATTN: Alan Berliner, Robert Treat Center, 50 Park Place, Suite 825, Newark, NJ, 07102	Defendant	Reuben Bachrach v. Akorn et. Al.	Personal Injury	ESX-L- 2566-19	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Greer/Carr	ATTN: Michael Greer; Kimberly Simoes, Greer, Russell & Dent, PLLC, 117 North Broadway Street, Tupelo, MS, 38804	Defendant	Greer/Carr v. Akorn, et. al.	Personal injury/death	CV2019- 075	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Debra Cohen	Mashel Law, LLC, 500 Campus Drive, Suite 303, Morganville, NJ, 07751	Defendant	Debra Cohen v. Akorn, Inc.	Employment Discrimination	MON-L- 01363-19	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	James Shenan	151 Frontier Way, Tinton Falls, NJ, 07753	Defendant	James Shenan v. Akorn, Inc.	Employment Discrimination	DCR Docket No: ET08AB- 67348-E	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.

Case 20-11177-KBO Doc 434-1 Filed 08/07/20 Page 6 of 18

Akorn, Inc. Fresenius Kabi AG AC Stephen P. Lamb, Esquire, Daniel A. Mason, Esquire, Brendan, W. Sullivan, EsquirePaul, Weiss, Rifkind, Wharton & Garrison LLP, 500 Delaware Avenue, Suite Plaintiff and Counterclaim Defendant Akorn, Inc. v. Fresenius Kabi AG Akorn, Inc. v. Fresenius Kabi AG No. 535, 2018	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Lamb, Esquire, Daniel A. Mason, Esquire, Brendan, W. Sullivan, EsquirePaul, Weiss, Rifkind, Wharton & Garrison LLP, 500 Delaware		and counter-claims related to litigation and possible
Mason, Esquire, Brendan, W. Sullivan, EsquirePaul, Weiss, Rifkind, Wharton & Garrison LLP, 500 Delaware		counter-claims related to litigation and possible
Esquire, Brendan, W. Sullivan, EsquirePaul, Weiss, Rifkind, Wharton & Garrison LLP, 500 Delaware		related to litigation and possible
Brendan, W. Sullivan, EsquirePaul, Weiss, Rifkind, Wharton & Garrison LLP, 500 Delaware		litigation and possible
Sullivan, EsquirePaul, Weiss, Rifkind, Wharton & Garrison LLP, 500 Delaware		possible
EsquirePaul, Weiss, Rifkind, Wharton & Garrison LLP, 500 Delaware		
Weiss, Rifkind, Wharton & Garrison LLP, 500 Delaware		litigation.
Wharton & Garrison LLP, 500 Delaware		
Garrison LLP, 500 Delaware		
500 Delaware		
1 (A.V.) (1111) (A.V.)		
200 , PO Box		
32,		
Wilmington,		
DE, 19899-		
0032		
ATTN:Samuel		
T. Hirzel,		
Esquire,		
Elizabeth A.		
DeFelice,		
Esquire,		
Heyman Enerio		
Gattuso &		
Hirzel LLP,		
300 Delaware		
Avenue, Suite		
200, Wilmington,		
DE, 19801		
DE, 19001		
ATTN: Ryan		
P. Newell,		
Esquire,		
Connolly		
Gallagher,		
LLP, The Brandywine		
Building, 1000		
West Street,		
Suite 1400,		
Wilmington,		
DE, 19801		
ATTN, Donald		
ATTN: Donald		
J. Wolfe, Jr., Esq., Michael		
A. Pittenger,		
Esq., T. Brad		
Davey, Esq.,		
Jacob R.		
Kirkham, Esq.,		
Elizabeth M.		
Taylor, Esq.,		
Matthew F.		
Davis,		
Esq.Potter Anderson &		
Corroon LLP,		

		T	1	Т	1	1		
		1313 N.						
		Market Street,						
		Hercules Plaza,						
		6th Floor,						
		Wilmington,						
		DE, 19801						
Akorn, Inc.	Gabelli &	ATTN: David	Defendant	In Re: Akorn,	Direct Claim	1:18-cv-	Active	Claims,
	Company, Inc	M. Goldman,		Inc. Data	(Class Action)	01713		defenses,
		Esq, One		Integrity				crossclaims
		Corporate		Securities				and
		Center, 401		Litigation				counter-claims
		Theodore						related to
		Fremd Avenue,						litigation and
		Rye, NY,						possible
		10580						litigation.
		ATTN:						
		Al IN: Abraham						
		Alexander, Avi						
		Josefson, John						
		James Rizio-						
		Hamilton, Kate						
		Whitman						
		Aufses, Kurt						
		Michael						
		Hunciker,						
		Bernstein						
		Litowitz						
		Berger &						
		Grossmann,						
		1251 6th Ave,						
		New York,						
		NY, 10020						
		ATTN:						
		Andrew John						
		Entwistle,						
		Andrew						
		Mitchell Sher,						
		Arthur Vincent						
		Nealon,						
		Brendan J.						
		Brodeur,						
		Joshua Killion						
		Porter, Robert						
		Nicholas						
		Cappucci,						
		Vincent						
		Rodger						
		Cappucci,						
		Entwistle &						
		Cappucci, 299						
		Park Ave 20th						
		floor, New						
		York, NY,						
Akorn, Inc.	Johnny	10171 ATTN: Jeremy	Defendant	Wickstrom v.	Shareholder	1:19-cv-	Active	Claims,
	Wickstrom	A. Lieberman,		Akorn, et. al.	Violations of	01299	1 1 2 2 1 7 0	defenses,
		J. Alexander		(Consolidated	10-b-5, S/A			crossclaims
		Hood II,		with In Re	- ,/			and
		Jonathan D.		Akorn DI)				counter-claims
		Lindenfeld,		ĺ				related to
		POMERANTZ						litigation and

	T	1	1	1	1	1	1	
		LLP, 600 Third						possible
		Avenue, 20th						litigation.
		Floor, New						
		York, NY,						
		10016						
		ATTN: Patrick						
		V. Dahlstrom,						
		POMERANTZ						
		LLP, Ten						
		South LaSalle						
		Street, Suite						
		3505, Chicago,						
		IL, 60603						
		ATTN: Phillip						
		C. Kim and						
		Laurence M.						
		Rosen, The						
		Rosen Law						
		Firm, 275]	
		Madison					1	
		Avenue, 40th]	
		Floor, New						
		York, NY,						
		10016						
		ATTN: J.						
		Alexander						
		Hood, II,						
		Jeremey Alan						
		Leiberman,						
		Pomerantz						
		LLP, 600 Third						
		Avenue, Floor						
		20, New York,						
		NY, 10016	- a -	m	T. 61.	4.40		at t
Akorn, Inc.	Twin Master	ATTN:	Defendant	Twin Master	Direct Claim	1:19-cv-	Active	Claims,
	Fund, Ltd.	Andrew Dylan		Fund, Ltd. et al	(Opt-Out from	03648		defenses,
		Campbell, John		v. Akorn, Inc. et	Class)			crossclaims
		Blair Haarlow		al				and
		Jr., Novack &					1	counter-claims
		Macey LLP,						related to
		100 North						litigation and
		Riverside					1	possible
		Plaza, Chicago,					1	litigation.
		IL, 60606					1	
		1					1	
		ATTN:]	
		Lawrence						
		Rolnick, Marc						
							1	
		B. Kramer,					1	
		Thomas E.					1	
		Redburn,					1	
		Michael J.						
		Hampson,						
		Lowenstein						
		Sandler LLP,					1	
							1	
	1	1251 Avenue	l	1	1	İ	1	
		of the						
		of the Americas, New						
		of the						

Case 20-11177-KBO Doc 434-1 Filed 08/07/20 Page 9 of 18

Akorn, Inc.	Manikay Master Fund, LP	ATTN: Andrew Dylan Campbell, John Blair Haarlow Jr., Novack & Macey LLP, 100 North Riverside Plaza, Chicago, IL, 60606 ATTN: Lawrence Rolnick, Richard Bodnar, Jennifer Ann Randolph, Michael J. Hampson, Lowenstein Sandler LLP, 1251 Avenue of the Americas, New York, NY, 10020 ATTN: Andrew Dylan Campbell, John Blair Haarlow Jr., Novack & Macey LLP, 100 North Riverside Plaza, Chicago, IL, 60606 ATTN: Lawrence Rolnick, Richard Bodnar, Jennifer Ann Randolph, Michael J. Hampson, Lowenstein Sandler LLP, 1251 Avenue of the Americas, New York, NY,	Defendant	Manikay Master Fund LP et al v. Akorn, Inc.	Direct Claim (Opt-Out from Class)	1:19-cv- 04651	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Fir Tree Value Master Fund LP	ATTN: Andrew Dylan Campbell, John Blair Haarlow Jr., Novack & Macey LLP, 100 North Riverside	Defendant	Fir Tree Master Fund V. Akorn, Inc.	Direct Claim (Opt-Out from Class)	1:19-cv- 07418	Active	Claims, defenses, crossclaims and counter-claims related to litigation and

-	1	_			_			
		Plaza, Chicago, IL, 60606 ATTN: Lawrence Rolnick, Richard						possible litigation.
		Bodnar, Jennifer Ann Randolph, Michael J. Hampson, Sheila Sadighi, Lowenstein Sandler LLP, 1251 Avenue						
		of the Americas, New York, NY, 10020						
Akorn, Inc.	AQR Absolute Return Master Account, L.P.	ATTN: Jacob Buchdahl, Arun Subramanian, Mark Hatch- Miller, Susman Godfrey LLP, 1301 Avenue of the Americas, 32nd Floor, New York, NY, 10017 ATTN: Suyash Agrawal, Massey & Gail LLP, 50 East Washington Street, Suite 400, Chicago,	Defendant	AQR Funds - AQR Multi- Strategy Alternative Fund et al v. Akorn, Inc. et al	Direct Claim (Opt-Out from Class)	1:20-CV- 00434	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	U.S. Consults, LLC	IL, 60602 ATTN: Sam Jenkins, 2419 Kings Highway, Shreveport, LA, 71103	Defendant	U.S. Consults, LLC v. Akorn, Inc.	Breach of Contract	695218-22	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Tina M Spence	834 W Division St, Decatur, IL, 62526	Defendant	n/a	Employment Discrimination	Charge No. 440-2020-01702	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Tyler Kreitz	ATTN: Christopher D. Moon, Moon	TBD	TBD	False Advertising	TBD	Active	Claims, defenses, crossclaims

		Law, 600 West Broadway, Suite 700, San Diego, CA, 92101						and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Confidential / ZOSTRIX demand letter	ATTN: Jason P Sultzer, The Sultzer Law Group, 85 Civic Center Plaza, Suite 200, Poughkeepsie, NY, 12601	TBD	TBD	False Advertising	TBD	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Tia A Waldbeesser	3903 EAST CAMELOT CIRCLE, APT 303, DECATUR, IL, 62526	Defendant	n/a	Employment Discrimination	EEOC Charge No. 440-2020- 04886	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Walmart	ATTN: WALMART's Counsel, Tracy L Dixon Kutak Rock LLP, The Omaha Building, 1650 Farnam Street, Omaha, NE, 68102-2103	TBD	TBD	Product Liability	TBD	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc.	Cigna	ATTN: Robert A. Burke, 900 Cottage Grove Road, Bloomfield, CT, 06002	Co- conspirators	Cigna Complaint	Antitrust Pricing	2:20-cv- 02711	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Hi-Tech Pharmacal Co., Inc.	Confidential	Plaintiff's Liason Counsel: Francisco R Maderal, Coslon Hicks Eidson, 255 Alhambra Circle Penthouse, Coral Gables, FL 33134	Defendant	In re: Zantac (Ranitidine) Products Liability Litigation	Product Liability	9:20-md- 02924-RLR	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Hi-Tech Pharmacal Co., Inc.	Confidential	Plaintiff's Liason Counsel: Francisco R Maderal, Coslon Hicks Eidson, 255 Alhambra	Defendant	Ralph Koepsel v. Boehringer Ingelheim Pharmaceuticals, Inc., et al	Product Liability	cv-80882- RLR	Active	Claims, defenses, crossclaims and counter-claims related to litigation and

Case 20-11177-KBO Doc 434-1 Filed 08/07/20 Page 12 of 18

		Circle Penthouse, Coral Gables, FL 33134						possible litigation.
Akorn, Inc., Akorn Sales, Inc. and Hi- Tech Pharmacal Co., Inc.	Kathryn Eaton	ATTN: Kyle R Taylor, Affleck Greene McMurthy LLP, 365 Bay Street, Suite 200, Toronto, ON M5H2V1	Defendant	Statement of Claim -Federal Court Proposed Class Proceeding (CANADA)	Price Fixing Class Action	Court File No. T-607- 20	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Hi-Tech Pharmacal Co., Inc.	State of Louisiana	ATTN: Jeff Landry, Keetsie Gunnels, and Nicholas Diez, Office of the Attorney General, 1885 North 3rd Street, Baton Rouge, LA, 70802 ATTN: Jerald Block, BLOCK LAW FIRM, 422 East First Street, Post Office Box 108, Thibodeaux, LA, 70302 ATTN: W. Daniel "Dee" Miles, III, G. Lance Gould, Alison D. Hawthorne, BEASLEY, ALLEN CROW METHVIN, PORTIS & MILES, P.C., 272 Commerce Street, Post Office Box 4160, Montgomery, AL, 36103 ATTN: Ernest L. Johnson, ERNEST L. JOHNSON & ASSOCIATES, 3313 Government	Defendant	State of Louisiana v.Abbott Laboratories Inc.,et al.	Medicaid Reimbursment	Case # C624522	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.

		Street, Baton						
		Rouge, LA, 70806						
		ATTN: Patrick C. Morrow, Richard T. Haik, Jr., James P. Ryan, MORROW, MORROW, RYAN, BASSETT & HAIK, 324 W. Landry Street,						
		Opelousas, LA, 70570						
Akorn, Inc.	Provepharm, Inc.	ATTN: Felice B. Galant, Norton Rose Fulbright US LLP, 1301 Avenue of the Americas, New York, NY, 10019-6022	Defendant	Provepharm, Inc. v. Akorn, Inc.	False Advertising	Case No. 17-cv- 007087 (SJF) (AKT)	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc., Hi-Tech Pharmacal and Versapharm	Generic Pharmaceuticals Pricing Antitrust Litigation	ATTN: Dianne M. Nast, Esq., NastLaw LLC, 1101 Market Street, Suite 2801, Philadelphia, PA, 19107 ATTN: Roberta Liebenberg, Esq., Fine, Kaplan, and Black R.P.C., One South Broad Street, 23rd Floor, Philadelphia, PA, 19107 ATTN: W. Joseph Nielsen, Esq., Connecticut Attorney General's Office, 55 Elm St, Hartford, CT, 06106 ATTN: Jan P. Levine, Esq., Pepper Hamilton LLP, 3000 Two Logan Square,	Defendant	In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724	Price Fixing Class Action	EPA MDL No. 16-MD- 2724	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.

		Eighteenth & Arch Streets, Philadelphia, PA, 19103- 2799						
Akorn, Inc., Akorn Sales, Inc., and Hi- Tech Pharmacal Co., Inc.	America's 1st Choice of South Carolina, Inc.	ATTN: Anthony Christina, Lowey Dannenberg PC, One Tower Bridge, 100 Front St., Suite 520, West Conshohocken, PA, 19428-297	Defendant	America's 1st Choice of South Carolina, Inc., et al.	Antitrust Matter	190702094	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.
Akorn, Inc., Akorn Sales, Inc., Hi-Tech Pharmacal Co., Inc., and Versapharm Inc.	Blue Cross and Blue Shield of North Carolina, et al.	ATTN: Anthony Christina, Lowey Dannenberg PC, One Tower Bridge, 100 Front St., Suite 520, West Conshohocken, PA, 19428- 2977	Defendant	Blue Cross and Blue Shield of North Carolina, et al.	Antitrust matter	200500347	Active	Claims, defenses, crossclaims and counter-claims related to litigation and possible litigation.

Causes of Action Related to Rejected Contracts

#	Debtor Counterparty		Address	Description of Contract	Nature	
1	Akorn, Inc.	AZAD Fine Chemicals Ltd.	Attn: Jennifer Baronian, 177 Place Frontenac, Point-Claire, QC, H9R 4Z7, Canada	Referral Agreement	Claims, defenses, crossclaims and counter-claims related to rejected contracts.	
2	VersaPharm Incorporated	Ei Inc.	Attn: Roger Martin, President, 2865 North Cannon Boulevard, Kannapolis, NC, 28083	Amendment 1 to the Manufacturing and Technical Services Agreement Dated April 4, 2013	Claims, defenses, crossclaims and counter-claims related to rejected contracts.	
3	VersaPharm Incorporated	Ei Inc.	Attn: President, 2865 North Cannon Boulevard, Kannapolis, NC, 28083	Manufacturing and Technical Services Agreement	Claims, defenses, crossclaims and counter-claims related to rejected contracts.	
4	Hi-Tech Pharmacal Co., Inc.	RxElite Inc.	Attn: COO, 1404 N. Main Street, Suite 200, Meridian, ID, 83642	Development, Supply and Marketing Agreement dated June 14, 2008	Claims, defenses, crossclaims and counter-claims related to rejected contracts.	
5	Hi-Tech Pharmacal Co., Inc.	RxElite Inc. Finetech Pharmaceutical LTd, a wholly-owned subsidiary of RxElite, Inc.	Attn: COO, 1404 N. Main Street, Suite 200, Meridian, ID, 83642 Attn: 33 Hanarkissim Street, Nesher, Israel 36608	First Amendment to the Development, Supply and Marketing Agreement dated December 15, 2008	Claims, defenses, crossclaims and counter-claims related to rejected contracts.	
6	Akorn, Inc.	Namigen, LLC	Attn: Nathan Barishansky, President/CEO, 2 University	Exclusive License, Supply and Commercialization Agreement	Claims, defenses, crossclaims and	

			Plaza, Suite 204, Hackensack, NJ, 07601		counter-claims related to rejected contracts.
7	Akorn, Inc.	NASDAQ OMX Corporate Solutions, LLC	One Liberty Plaza, 165 Broadway, New York, NY, 10006	Master Services Agreement	Claims, defenses, crossclaims and counter-claims related to rejected contracts.
8	Akorn, Inc.	NASDAQ OMX Corporate Solutions, LLC	195 Broadway, 9th Floor, New York, NY, 10006	Service Order Between NASDAQ OMX Corportate Solutions Inc. and Customer	Claims, defenses, crossclaims and counter-claims related to rejected contracts.
9	Akorn, Inc.	NASDAQ OMX Corporate Solutions, LLC	One Liberty Plaza, 165 Broadway, New York, NY, 10006	Service Order Between NASDAQ OMX Corportate Solutions Inc. and Customer	Claims, defenses, crossclaims and counter-claims related to rejected contracts.
10	Akorn, Inc.	NASDAQ OMX Corporate Solutions, LLC	One Liberty Plaza, 165 Broadway, New York, NY, 10006	Service Order Between NASDAQ OMX Corportate Solutions Inc. and Customer	Claims, defenses, crossclaims and counter-claims related to rejected contracts.
11	Akorn, Inc.	Fresenius Kabi Austria GMBH	Attn: Johann Schlogl and Anton Gerdenitsch, Hafnerstrasse 36, Graz, 8055, Austria	Supply Agreement	Claims, defenses, crossclaims and counter-claims related to rejected contracts.
12	Hi-Tech Pharmacal Co., Inc.	Septodont Inc.	Attn: Michael V. and Paul Mondock, 416 S. Taylor Avenue, Louisville, CO, 80027	Supply Agreement Effective September 14, 2011	Claims, defenses, crossclaims and counter-claims related to rejected contracts.
13	Hi-Tech Pharmacal Co., Inc.	Septodont Inc.	416 S TAYLOR AVENUE, LOUISVILLE, CO, 80027	Septodont licensing amd 1	Claims, defenses, crossclaims and counter-claims related to rejected contracts.
14	Hi-Tech Pharmacal Co., Inc.	Septodont Inc.	Attn: Todd Beechey, Chief Financial Officer, 416 S. Taylor Avenue, Louisville, CO, 80027	Amendment No. 2 to Supply Agreement Effective October 1, 2019	Claims, defenses, crossclaims and counter-claims related to rejected contracts.

1. Contract Causes of Action

This **Exhibit A** includes contracts and leases to which one or more Debtors are a party. Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable, expressly reserve all claims and Causes of Action against any Entity, based in whole or in part upon any and all contracts and leases to which any Debtor is a party or pursuant to which any Debtor has any rights whatsoever, regardless of whether such contract or lease is included on **Exhibit A**. The claims and Causes of Actions reserved include, without limitation, Causes of Action against vendors, suppliers of goods or services, customers, or any other parties, unless such claims or Causes of Action were previously released through the Plan or separate written agreement executed by the Debtors: (a) for overpayments, back charges, duplicate payments, improper holdbacks, deposits, warranties, guarantees, indemnities, recoupment, or setoff; (b) for wrongful or improper termination, suspension of services or supply of goods, or failure to meet other contractual

or regulatory obligations; (c) for failure to fully perform or to condition performance on additional requirements under contracts with any one or more of the Debtors before the assumption or rejection, if applicable, of such contracts; (d) for payments, deposits, holdbacks, reserves, or other amounts owed by any creditor, utility, supplier, vendor, insurer, surety, factor, lender, bondholder, lessor, or other party; (e) for any liens, including mechanic's, artisan's, materialmen's, possessory, or statutory liens held by any one or more of the Debtors; (f) for environmental or contaminant exposure matters against landlords, lessors, environmental consultants, environmental agencies, or suppliers of environmental services or goods; (g) for counter-claims and defenses related to any contractual obligations; (h) for any turnover actions arising under section 542 or 543 of the Bankruptcy Code; and (i) for unfair competition, interference with contract or potential business advantage, breach of contract, infringement of intellectual property, or any business tort claims. Additionally, on or around July 29, 2020, each of the Debtors filed its Schedules, which included, among other things, claims and Causes of Action each of the Debtors had reflected as a liability on its books and records, and its Statement of Financial Affairs, which details certain information regarding each Debtor's property (collectively, the "SoFAs"). Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity listed on (a) with respect to the schedules, Schedule A/B, Schedule D, Schedule E, Schedule F, Schedule G, and Schedule H of each Debtor and (b) the SoFA of each Debtor, in each case to the extent such Entities owe or may in the future owe money to the Debtors.

2. Tort Causes of Action

Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity based in whole or in part upon tort. The claims and Causes of Action reserved include Causes of Action against vendors, suppliers of goods and services, or any other parties: (a) for overpayments, back charges, duplicate payments, improper holdbacks, deductions owing or improper deductions taken, deposits, warranties, guarantees, indemnities, recoupment, or setoff; (b) for wrongful or improper termination, suspension of services or supply of goods, or failure to meet other contractual or regulatory obligations; (c) for failure to fully perform or to condition performance on additional requirements under contracts with any one or more of the Debtors before the assumption or rejection, if applicable, of such contracts; (d) for payments, deposits, holdbacks, reserves or other amounts owed by any creditor, utility, supplier, vendor, insurer, surety, factor, lender, bondholder, lessor or other party; (e) for any liens, including mechanics', artisans', materialmens', possessory or statutory liens held by any one or more of the Debtors; (f) arising out of environmental or contaminant exposure matters against landlords, lessors, environmental consultants, environmental agencies or suppliers of environmental services or goods; (g) for counter-claims and defenses related to any contractual obligations; and (h) for unfair competition, interference with contract or potential business advantage, breach of contract, infringement of intellectual property or any business tort claims. Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors, and the Plan Administrator, as applicable, expressly reserve all claims and Causes of Action against any Entity listed on Schedule A/B, Schedule D, Schedule E, and Schedule F of each Debtor to the extent such Entities owe or may in the future owe money to the Debtors. Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity listed on (a) with respect to the schedules, Schedule A/B, Schedule D, Schedule E, Schedule F, Schedule G, and Schedule H of each Debtor and (b) the SoFA of each Debtor, in each case to the extent such Entities owe or may in the future owe money to the Debtors.

3. Causes of Action Related to Insurance Policies

Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity based in whole or in part upon any and all insurance contracts, insurance policies, occurrence policies and occurrence contracts to which any Debtor is or was a party or pursuant to which any Debtor has any rights whatsoever, including Causes of Action against current or former insurance carriers, reinsurance carriers, insurance brokers, underwriters, occurrence carriers, or surety bond issuers relating to coverage, indemnity, contribution, reimbursement, overpayment of premiums and fees, breach of contract or any other matters. Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity listed on (a) with respect to the schedules, Schedule A/B, Schedule D, Schedule E, Schedule F, Schedule G, and Schedule H of each Debtor and (b) the SoFA of each Debtor, in each case to the extent such Entities owe or may in the future owe money to the Debtors.

4. Causes of Action Related to Deposits, Adequate Assurance Postings, and Other Collateral Postings

Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity based in whole or in part upon any and all postings of a security deposits, adequate assurance payment, or any other type of deposit or collateral owed by any creditor, lessor, utility, supplier, vendor, landlord, sub-lessee, assignee or other Entity. Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity listed on (a) with respect to the schedules, Schedule A/B, Schedule D, Schedule E, Schedule F, Schedule G, and Schedule H of each Debtor and (b) the SoFA of each Debtor, in each case to the extent such Entities owe or may in the future owe money to the Debtors.

5. Causes of Action Related to Liens

Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Cash Collateral Orders and/or any other order of this Bankruptcy Court, the Debtors and the Plan Administrator expressly reserve all Causes of Action based in whole or in part upon any and all liens regardless of whether such lien is specifically identified herein. Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity listed on (a) with respect to the schedules, Schedule A/B, Schedule D, Schedule E, Schedule F, Schedule G, and Schedule H of each Debtor and (b) the SoFA of each Debtor, in each case to the extent such Entities owe or may in the future owe money to the Debtors.

6. <u>Causes of Action Related to Defenses, Cross-Claims and Counter-claims Related to Litigation and Potential Litigation</u>

Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against or related to all Entities that are party to or that may in the future become party to litigation, arbitration, or any other type of adversarial proceeding or dispute resolution proceeding, whether formal or informal or judicial or non-judicial, including all actual or potential (a) contract and tort actions that may exist or may subsequently arise, (b) actions relating to environmental and product liability matters, and (c) actions arising out of, or relating to, the Debtors' intellectual property rights. For the avoidance of doubt, nothing herein shall be read as an admission as to the validity or allowance of any claim against any Debtor, and any and all prepetition claims against the Debtors that may be identified herein shall be treated in accordance with the Plan and the Bankruptcy Code. Unless

otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity listed on (a) with respect to the schedules, Schedule A/B, Schedule D, Schedule E, Schedule F, Schedule G, and Schedule H of each Debtor and (b) the SoFA of each Debtor, in each case to the extent such Entities owe or may in the future owe money to the Debtors.

7. Causes of Action Related to Accounts Receivable and Accounts

Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against or related to all Entities that owe or that may in the future owe money to the Debtors, regardless of whether such Entity is expressly identified in the Plan, this Plan Supplement, or any amendments thereto. Furthermore, the Debtors expressly reserve all Causes of Action against or related to all Entities who assert or may assert that the Debtors owe money to them. Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity listed on (a) with respect to the schedules, Schedule A/B, Schedule D, Schedule E, Schedule F, Schedule G, and Schedule H of each Debtor and (b) the SoFA of each Debtor, in each case to the extent such Entities owe or may in the future owe money to the Debtors.

8. Causes of Action Related to Taxes, Fees, and Tax or Fee Refunds or Credits

Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against or related to all Entities that owe or that may in the future owe money related to tax or fee refunds, credits, overpayments, recoupments or offsets that may be due and owing to the Debtors. Furthermore, the Debtors expressly reserve all Causes of Action against or related to all Entities who assert or may assert that the Debtors owe taxes to them. Unless otherwise released under Article VIII of the Plan or acquired under the Stalking Horse APA, the Debtors and the Plan Administrator, as applicable expressly reserve all claims and Causes of Action against any Entity listed on (a) with respect to the schedules, Schedule A/B, Schedule D, Schedule E, Schedule F, Schedule G, and Schedule H of each Debtor and (b) the SoFA of each Debtor, in each case to the extent such Entities owe or may in the future owe money to the Debtors.

The Debtors reserve all rights to amend, revise, or supplement this **Exhibit A** to the Plan Supplement, and any of the documents and designations contained herein, at any time before the Effective Date of the Plan, or any such other date as may be provided for by the Plan or by order of the Bankruptcy Court.

Exhibit B

Assumed Contracts and Leases List

Exhibit B

Assumed Contracts and Leases List

Unless otherwise provided for in the Plan, no Executory Contracts or Unexpired Leases are being assumed by the Debtors pursuant to this Plan Supplement.

Exhibit C

Description of Transaction Steps

Exhibit C

Description of Transaction Steps

To be filed at a later date.

Exhibit D

Identity and Terms of Compensation of the Plan Administrator

Exhibit D

Identity and Terms of Compensation of the Plan Administrator

The Debtors, in consultation with the Purchaser, have selected Drivetrain LLC to serve as the "<u>Plan Administrator</u>". The Plan Administrator's compensation will consist of \$25,000 per month and reimbursement of actual and necessary out of pocket costs and expenses.